-
1
-
-
33645694582
-
Immunosuppression: Evolution in practice and trends, 1994-2004
-
Meier-Kriesche HU, Li S, Gruessner RW et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant 2006: 6: 1111.
-
(2006)
Am J Transplant
, vol.6
, pp. 1111
-
-
Meier-Kriesche, H.U.1
Li, S.2
Gruessner, R.W.3
-
2
-
-
0029006409
-
Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection
-
European Mycophenolate Mofetil Cooperative Study Group
-
European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995: 345: 1321.
-
(1995)
Lancet
, vol.345
, pp. 1321
-
-
-
3
-
-
0029115531
-
Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group
-
Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995: 60: 225.
-
(1995)
Transplantation
, vol.60
, pp. 225
-
-
Sollinger, H.W.1
-
4
-
-
0006986048
-
A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation
-
Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group
-
Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 1996: 61: 1029.
-
(1996)
Transplantation
, vol.61
, pp. 1029
-
-
-
5
-
-
0034660104
-
Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection
-
Ojo AO, Meier-Kriesche HU, Hanson JA et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000: 69: 2405.
-
(2000)
Transplantation
, vol.69
, pp. 2405
-
-
Ojo, A.O.1
Meier-Kriesche, H.U.2
Hanson, J.A.3
-
6
-
-
0031024728
-
Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups
-
Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C. Mycophenolate mofetil in renal allograft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 1997: 63: 39.
-
(1997)
Transplantation
, vol.63
, pp. 39
-
-
Halloran, P.1
Mathew, T.2
Tomlanovich, S.3
Groth, C.4
Hooftman, L.5
Barker, C.6
-
7
-
-
0346525123
-
Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection
-
Meier-Kriesche HU, Steffen BJ, Hochberg AM et al. Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. Am J Transplant 2003: 3: 68.
-
(2003)
Am J Transplant
, vol.3
, pp. 68
-
-
Meier-Kriesche, H.U.1
Steffen, B.J.2
Hochberg, A.M.3
-
8
-
-
0034654107
-
Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group
-
Miller J, Mendez R, Pirsch JD, Jensik SC. Safety and efficacy of tacrolimus in combination with mycophenolate mofetil (MMF) in cadaveric renal transplant recipients. FK506/MMF Dose-Ranging Kidney Transplant Study Group. Transplantation 2000: 69: 875.
-
(2000)
Transplantation
, vol.69
, pp. 875
-
-
Miller, J.1
Mendez, R.2
Pirsch, J.D.3
Jensik, S.C.4
-
9
-
-
56349147470
-
-
Nutley, NJ, USA: Roche Pharmaceuticals. Revised October
-
MMF Prescribing Information. Nutley, NJ, USA: Roche Pharmaceuticals. Revised October 2005.
-
(2005)
MMF Prescribing Information
-
-
-
10
-
-
0042536429
-
Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation
-
Knoll GA, Mac Donald I, Khan A, Van Walraven C. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol 2003: 14: 2381.
-
(2003)
J Am Soc Nephrol
, vol.14
, pp. 2381
-
-
Knoll, G.A.1
Mac Donald, I.2
Khan, A.3
Van Walraven, C.4
-
11
-
-
0037663784
-
The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation
-
Pelletier RP, Akin B, Henry ML, Elkhammas EA, Rajab A, Ferguson RM. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant 2003: 17: 200.
-
(2003)
Clin Transplant
, vol.17
, pp. 200
-
-
Pelletier, R.P.1
Akin, B.2
Henry, M.L.3
Elkhammas, E.A.4
Rajab, A.5
Ferguson, R.M.6
-
12
-
-
28644442483
-
Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal recipients
-
Tierce JC, Porterfield-Baxa J, Petrilla AA, Kilburg A, Ferguson RM. Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal recipients. Clin Transplant 2005: 19: 779.
-
(2005)
Clin Transplant
, vol.19
, pp. 779
-
-
Tierce, J.C.1
Porterfield-Baxa, J.2
Petrilla, A.A.3
Kilburg, A.4
Ferguson, R.M.5
-
13
-
-
0034889041
-
Adverse gastrointestinal effects of mycophenolate mofetil: Aetiology, incidence and management
-
B ehrend M. Adverse gastrointestinal effects of mycophenolate mofetil: aetiology, incidence and management. Drug Saf 2001: 24: 645.
-
(2001)
Drug Saf
, vol.24
, pp. 645
-
-
Behrend, M.1
-
15
-
-
33750587517
-
Using GI-specific patient outcome measures in renal transplant patients: Validation of the GSRS and GIQLI
-
Kleinman L, Kilburg A, Machnicki G et al. Using GI-specific patient outcome measures in renal transplant patients: Validation of the GSRS and GIQLI. Qual Life Res 2006: 15: 1223.
-
(2006)
Qual Life Res
, vol.15
, pp. 1223
-
-
Kleinman, L.1
Kilburg, A.2
Machnicki, G.3
-
16
-
-
0041360482
-
Overview of large database analysis in renal transplantation
-
Kaplan B, Schold J, Meier-Kriesche HU. Overview of large database analysis in renal transplantation. Am J Transplant 2003: 3: 1052.
-
(2003)
Am J Transplant
, vol.3
, pp. 1052
-
-
Kaplan, B.1
Schold, J.2
Meier-Kriesche, H.U.3
-
17
-
-
12144273473
-
Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil
-
Hardinger K, Brennan DC, Lowell J, Schnitzler M. Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transplant Int 2004: 17: 609.
-
(2004)
Transplant Int
, vol.17
, pp. 609
-
-
Hardinger, K.1
Brennan, D.C.2
Lowell, J.3
Schnitzler, M.4
-
18
-
-
33747494883
-
Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure
-
Bunnapradist S, Lentine KL, Burroughs TE et al. Mycophenolate mofetil dose reductions and discontinuations after gastrointestinal complications are associated with renal transplant graft failure. Transplantation 2006: 82: 102.
-
(2006)
Transplantation
, vol.82
, pp. 102
-
-
Bunnapradist, S.1
Lentine, K.L.2
Burroughs, T.E.3
-
19
-
-
51749098832
-
Gastrointestinal event associated dose reduction and discontinuation of renal transplant patients receiving MMF
-
Legoretta AP, Robinson M, Gilmore AS, Feng S. Gastrointestinal event associated dose reduction and discontinuation of renal transplant patients receiving MMF. Transplantation 2006: 82(Suppl. 3): 485.
-
(2006)
Transplantation
, vol.82
, Issue.SUPPL. 3
, pp. 485
-
-
Legoretta, A.P.1
Robinson, M.2
Gilmore, A.S.3
Feng, S.4
-
20
-
-
35748956704
-
A retrospective analysis of immunosuppression compliance, dose reduction and discontinuation in kidney transplant recipients
-
Takemoto SK, Pinsky BW, Schnitzler MA et al. A retrospective analysis of immunosuppression compliance, dose reduction and discontinuation in kidney transplant recipients. Am J Transplant 2007: 7: 2704.
-
(2007)
Am J Transplant
, vol.7
, pp. 2704
-
-
Takemoto, S.K.1
Pinsky, B.W.2
Schnitzler, M.A.3
-
21
-
-
56349121245
-
Diarrhea following renal transplantation: Influences of immunosuppression and implications for survival
-
Salvalaggio P, Pinsky B, Takemoto SK et al. Diarrhea following renal transplantation: Influences of immunosuppression and implications for survival. Transplantation 2006: 82(Suppl. 3): 480.
-
(2006)
Transplantation
, vol.82
, Issue.SUPPL. 3
, pp. 480
-
-
Salvalaggio, P.1
Pinsky, B.2
Takemoto, S.K.3
-
22
-
-
56349115925
-
Graft outcomes and healthcare costs in kidney transplant recipients who develop diarrhea or dyspepsia and discontinue use of mycophenolate mofetil
-
Legoretta AP, Kang N, Gilmore AS et al. Graft outcomes and healthcare costs in kidney transplant recipients who develop diarrhea or dyspepsia and discontinue use of mycophenolate mofetil. Transplantation 2006: 82(Suppl. 3): 484.
-
(2006)
Transplantation
, vol.82
, Issue.SUPPL. 3
, pp. 484
-
-
Legoretta, A.P.1
Kang, N.2
Gilmore, A.S.3
-
23
-
-
33745810228
-
Severe diarrhea in renal transplant patients: Results of the DIDACT study
-
Maes B, Hadaya K, de Moor B et al. Severe diarrhea in renal transplant patients: Results of the DIDACT study. Am J Transplant 2006: 6: 1466.
-
(2006)
Am J Transplant
, vol.6
, pp. 1466
-
-
Maes, B.1
Hadaya, K.2
de Moor, B.3
-
24
-
-
33751527410
-
Improvement in social functioning in kidney transplant patients after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium (myfortic®): Three case studies
-
Shah T. Improvement in social functioning in kidney transplant patients after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium (myfortic®): Three case studies. Drugs 2006: 66 (Suppl. 2): 15.
-
(2006)
Drugs
, vol.66
, Issue.SUPPL. 2
, pp. 15
-
-
Shah, T.1
-
25
-
-
33751539416
-
Resolution of gastrointestinal side effects in a patient converted from mycophenolate mofetil to enteric-coated mycophenolate sodium (myfortic®)
-
Tuncer M. Resolution of gastrointestinal side effects in a patient converted from mycophenolate mofetil to enteric-coated mycophenolate sodium (myfortic®). Drugs 2006: 66(Suppl. 2): 9.
-
(2006)
Drugs
, vol.66
, Issue.SUPPL. 2
, pp. 9
-
-
Tuncer, M.1
-
27
-
-
33750953529
-
Consequences of immunosuppression minimization following diagnosis of gastrointestinal complications in renal transplant
-
Schnitzler MA, Hardinger KL, Burroughs TE, Irish WD, Lentine K, Brennan D. Consequences of immunosuppression minimization following diagnosis of gastrointestinal complications in renal transplant. Am J Transplant 2005: 5(Suppl. 11): 242.
-
(2005)
Am J Transplant
, vol.5
, Issue.SUPPL. 11
, pp. 242
-
-
Schnitzler, M.A.1
Hardinger, K.L.2
Burroughs, T.E.3
Irish, W.D.4
Lentine, K.5
Brennan, D.6
-
28
-
-
0033609476
-
A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation
-
van Gelder T, Hilbrands LB, Vanrenterghem Y et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999: 68: 261.
-
(1999)
Transplantation
, vol.68
, pp. 261
-
-
van Gelder, T.1
Hilbrands, L.B.2
Vanrenterghem, Y.3
-
29
-
-
27644434992
-
The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation
-
van Gelder T, Shaw LM. The rationale for and limitations of therapeutic drug monitoring for mycophenolate mofetil in transplantation. Transplantation 2005: 80: S244.
-
(2005)
Transplantation
, vol.80
-
-
van Gelder, T.1
Shaw, L.M.2
-
30
-
-
33846591856
-
Non-infectious gastrointestinal complications of mycophenolic acid therapy: A consequence of local GI toxicity?
-
Arns W. Non-infectious gastrointestinal complications of mycophenolic acid therapy: A consequence of local GI toxicity? Transplant Proc 2007: 39: 88.
-
(2007)
Transplant Proc
, vol.39
, pp. 88
-
-
Arns, W.1
-
31
-
-
15844416494
-
Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil
-
Arns W, Breuer S, Choudhury S et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant 2005: 19: 199.
-
(2005)
Clin Transplant
, vol.19
, pp. 199
-
-
Arns, W.1
Breuer, S.2
Choudhury, S.3
-
32
-
-
1342346699
-
Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients
-
On Behalf of the ERLB301 Study Group
-
Salvadori M, Holzer H, de Mattos A et al, On Behalf of the ERLB301 Study Group. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004: 4: 231.
-
(2004)
Am J Transplant
, vol.4
, pp. 231
-
-
Salvadori, M.1
Holzer, H.2
de Mattos, A.3
-
33
-
-
33747104149
-
Long-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic®) is safe in kidney transplant patients
-
On Behalf of the ERL B301 Study Group
-
Salvadori M, Holzer H, Civati G et al. On Behalf of the ERL B301 Study Group. Long-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic®) is safe in kidney transplant patients. Clinical Nephrol 2006: 66: 112.
-
(2006)
Clinical Nephrol
, vol.66
, pp. 112
-
-
Salvadori, M.1
Holzer, H.2
Civati, G.3
-
34
-
-
1342325540
-
Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: Results of a 1-year study
-
On behalf of the ERL B302 Study Group
-
Budde K, Curtis J, Knoll G et al. On behalf of the ERL B302 Study Group. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: Results of a 1-year study. Am J Transplant 2004: 4: 237.
-
(2004)
Am J Transplant
, vol.4
, pp. 237
-
-
Budde, K.1
Curtis, J.2
Knoll, G.3
-
35
-
-
33747119649
-
Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS, myfortic®)
-
Budde K, Knoll G, Curtis J et al. Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPS, myfortic®). Clin Nephrol 2006: 66: 103.
-
(2006)
Clin Nephrol
, vol.66
, pp. 103
-
-
Budde, K.1
Knoll, G.2
Curtis, J.3
-
36
-
-
33750950096
-
Conversion to enteric-coated mycophenolate sodium from various doses of mycophenolate mofetil: Results of a prospective international multicenter trial in maintenance renal transplant patients receiving cyclosporine
-
ERL2405-DE02 Study Group
-
Nashan B, Suwelack B, Ivens K et al. ERL2405-DE02 Study Group. Conversion to enteric-coated mycophenolate sodium from various doses of mycophenolate mofetil: Results of a prospective international multicenter trial in maintenance renal transplant patients receiving cyclosporine. Transplant Proc 2006: 38: 2856.
-
(2006)
Transplant Proc
, vol.38
, pp. 2856
-
-
Nashan, B.1
Suwelack, B.2
Ivens, K.3
-
37
-
-
17844395233
-
Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients
-
myPROMS LatAm Study Group
-
Massari P, Duro-Garcia V, Girón F et al. myPROMS LatAm Study Group. Safety assessment of the conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in stable renal transplant recipients. Transplant Proc 2005: 37: 916.
-
(2005)
Transplant Proc
, vol.37
, pp. 916
-
-
Massari, P.1
Duro-Garcia, V.2
Girón, F.3
-
38
-
-
33746473566
-
Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: Results of a 12-month, single-blind, randomized, parallel-group, multicenter study
-
Kobashigawa JA, Renlund DG, Gerosa G et al. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study. J Heart Lung Transplant 2006: 25: 935.
-
(2006)
J Heart Lung Transplant
, vol.25
, pp. 935
-
-
Kobashigawa, J.A.1
Renlund, D.G.2
Gerosa, G.3
-
39
-
-
33744494308
-
Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium
-
Chan L, Mulgaonkar S, Walker R, Arns W, Ambühl P, Schiavelli R. Patient-reported gastrointestinal symptom burden and health-related quality of life following conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium. Transplantation 2006: 81: 1290.
-
(2006)
Transplantation
, vol.81
, pp. 1290
-
-
Chan, L.1
Mulgaonkar, S.2
Walker, R.3
Arns, W.4
Ambühl, P.5
Schiavelli, R.6
-
40
-
-
37349015946
-
Improvement in 3-month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients
-
Bolin P, Tanriover B, Zibari GB et al. Improvement in 3-month patient-reported gastrointestinal symptoms after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in renal transplant patients. Transplantation 2007: 84: 1443.
-
(2007)
Transplantation
, vol.84
, pp. 1443
-
-
Bolin, P.1
Tanriover, B.2
Zibari, G.B.3
-
41
-
-
27144546807
-
Questionnaire-based evaluation of gastrointestinal disorders in de novo renal-transplant patients receiving either mycophenolate mofetil or enteric-coated mycophenolate sodium
-
Kamar N, Oufroukhi L, Faure P et al. Questionnaire-based evaluation of gastrointestinal disorders in de novo renal-transplant patients receiving either mycophenolate mofetil or enteric-coated mycophenolate sodium. Nephrol Dial Transplant 2005: 20: 2231.
-
(2005)
Nephrol Dial Transplant
, vol.20
, pp. 2231
-
-
Kamar, N.1
Oufroukhi, L.2
Faure, P.3
-
42
-
-
33746700882
-
Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in patients with gastrointestinal side effects: Case studies
-
Boswell A, Rigg K, Shehata M. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in patients with gastrointestinal side effects: Case studies. Prog Transplant 2006: 16: 138.
-
(2006)
Prog Transplant
, vol.16
, pp. 138
-
-
Boswell, A.1
Rigg, K.2
Shehata, M.3
-
43
-
-
33751501957
-
Complete resolution of severe diarrhoea after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium (myfortic®) in a patient at high immunological risk
-
Breidenbach T, Spangenberg M, Nagel E. Complete resolution of severe diarrhoea after conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium (myfortic®) in a patient at high immunological risk. Drugs 2006: 66(Suppl. 2): 25.
-
(2006)
Drugs
, vol.66
, Issue.SUPPL. 2
, pp. 25
-
-
Breidenbach, T.1
Spangenberg, M.2
Nagel, E.3
-
44
-
-
56349110073
-
Dose and dose adjustments of mycophenolate sodium (EC-MPS, myfortic) and mycophenolate mofetil (MMF) in de novo renal transplant patients
-
On Behalf of the Direct Study Group
-
Budde K, Tuncer M, El-Shahawy M, On Behalf of the Direct Study Group. Dose and dose adjustments of mycophenolate sodium (EC-MPS, myfortic) and mycophenolate mofetil (MMF) in de novo renal transplant patients. Transplantation 2006: 82(Suppl. 3): 345.
-
(2006)
Transplantation
, vol.82
, Issue.SUPPL. 3
, pp. 345
-
-
Budde, K.1
Tuncer, M.2
El-Shahawy, M.3
-
45
-
-
33748804924
-
Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients presenting gastrointestinal disorders: A pilot study
-
Dumortier J, Gagnieu M-C, Salandre J et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in liver transplant patients presenting gastrointestinal disorders: A pilot study. Liver Transplant 2006: 12: 1342.
-
(2006)
Liver Transplant
, vol.12
, pp. 1342
-
-
Dumortier, J.1
Gagnieu, M.-C.2
Salandre, J.3
-
46
-
-
26644469263
-
Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regression of randomised trial data
-
Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regression of randomised trial data. Br Med J 2005: 331: 810.
-
(2005)
Br Med J
, vol.331
, pp. 810
-
-
Webster, A.C.1
Woodroffe, R.C.2
Taylor, R.S.3
Chapman, J.R.4
Craig, J.C.5
-
47
-
-
0030836803
-
Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection
-
Mayer AD, Dmitrewski J, Squifflet J-P et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection. Transplantation 1997: 64: 436.
-
(1997)
Transplantation
, vol.64
, pp. 436
-
-
Mayer, A.D.1
Dmitrewski, J.2
Squifflet, J.-P.3
-
48
-
-
0031001622
-
A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation
-
For the FK506 kidney transplant study group
-
Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. For the FK506 kidney transplant study group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997: 63: 977.
-
(1997)
Transplantation
, vol.63
, pp. 977
-
-
Pirsch, J.D.1
Miller, J.2
Deierhoi, M.H.3
Vincenti, F.4
Filo, R.S.5
-
49
-
-
0036943134
-
Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation
-
Trompeter R, Filler G, Webb NJA et al. Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation. Pediatr Nephrol 2002: 17: 141.
-
(2002)
Pediatr Nephrol
, vol.17
, pp. 141
-
-
Trompeter, R.1
Filler, G.2
Webb, N.J.A.3
-
50
-
-
0027141042
-
Erythromycin and other macrolides as prokinetic agents
-
Peeters TL Erythromycin and other macrolides as prokinetic agents. Gastroenterology 1993: 105: 1886.
-
(1993)
Gastroenterology
, vol.105
, pp. 1886
-
-
Peeters, T.L.1
-
51
-
-
22244431879
-
Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate
-
Kaplan B, Meier-Kriesche HU, Minnick P et al. Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate. Clin Transplant 2005: 19: 551.
-
(2005)
Clin Transplant
, vol.19
, pp. 551
-
-
Kaplan, B.1
Meier-Kriesche, H.U.2
Minnick, P.3
-
53
-
-
0038001525
-
Two- to three-fold increase in blood tacrolimus (FK506) level during diarrhea in liver-transplanted children
-
Berenguer JI, López-Espinosa JA, Ortega-López J et al. Two- to three-fold increase in blood tacrolimus (FK506) level during diarrhea in liver-transplanted children. Clin Transplant 2003: 17: 249.
-
(2003)
Clin Transplant
, vol.17
, pp. 249
-
-
Berenguer, J.I.1
López-Espinosa, J.A.2
Ortega-López, J.3
-
54
-
-
0036870921
-
Differential effect of diarrhea on FK506 versus cyclosporine A trough levels and resultant prevention of allograft rejection in renal transplant recipients
-
Maes BD, Lemahieu W, Kuypers D et al. Differential effect of diarrhea on FK506 versus cyclosporine A trough levels and resultant prevention of allograft rejection in renal transplant recipients. Am J Transplant 2002: 2: 989.
-
(2002)
Am J Transplant
, vol.2
, pp. 989
-
-
Maes, B.D.1
Lemahieu, W.2
Kuypers, D.3
-
55
-
-
4344561078
-
Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: A prospective study in one hundred de novo renal transplant recipients
-
Kuypers DRJ, Claes K, Evenepoel P et al. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: A prospective study in one hundred de novo renal transplant recipients. Clin Pharmacokinet 2004: 43: 741.
-
(2004)
Clin Pharmacokinet
, vol.43
, pp. 741
-
-
Kuypers, D.R.J.1
Claes, K.2
Evenepoel, P.3
|